Are you attending CureDuchenne FUTURES and have a question for Sarepta? Our team is available throughout the conference at our two booths and our Lego activity. Hope to see you there!

We’re thrilled to be a Diamond sponsor CureDuchenne’s FUTURES conference on May 23-26 and look forward to connecting with families in Orlando, Florida.

Are you heading to #ASGCT2024 in Baltimore? Come find our Sarepta team! We are excited to be among peers dedicated to gene and cell therapy.

Congratulations to Dr. Jerry Mendell on being named to the inaugural Time100 Health list! The list recognizes individuals who most influenced global health this year, and it is an acknowledgement of Dr. Mendell’s impact, innovation and achievement.

Today, we announced the opening of the 2024 Sarepta LGMD Grant Award Program. Open to non-governmental and patient advocacy organizations from across the globe, it aims to help shorten the LGMD diagnostic journey. Read our news release to learn more: bit.ly/3PsPCQK

Today, we announced the opening of Route 79, The Duchenne Scholarship Program. Created to help those affected by #Duchenne pursue their post-high-school educational goals, the program will award 25 scholarships. Read the press release to learn more: bit.ly/3ThgyFA

We just announced our Q4 and full-year 2023 financial results and recent corporate developments.

Leading up to #RareDiseaseDay , we’re talking about the importance of #newbornscreening for rare genetic diseases. We support the inclusion of Duchenne in existing #NBS programs so that that all patients have the chance to benefit from early diagnosis and treatment.

ICYMI: Earlier today, SRPT leadership shared an update on Study SRP-5051-201, MOMENTUM. Listen here: bit.ly/42lGp1Z

Listen live: SRPT leadership shares an update on Study SRP-5051-201, MOMENTUM. bit.ly/42lGp1Z

NEWS: Sarepta announces new positive data from Study 5051-201, MOMENTUM. Read the press release: bit.ly/3Uii2QI

The inclusion of Duchenne on Minnesota's newborn screening panel is a significant step forward. Congratulations to the advocates who supported this cause and kudos to the Advisory Committee for recognizing the urgent need. Because when it comes to Duchenne, time is muscle.

NEWS: Today we announced that screening is underway in Study SRP-9003-301, also known as EMERGENE, a Phase 3, multi-national, open-label study of investigational candidate SRP-9003 for the treatment of LGMD Type 2E. Read the press release: bit.ly/3U9mlxE

We just announced our preliminary fourth quarter and full-year 2023 net product revenues. Read our press release for details: bit.ly/47rh1ZC

We just announced our Q3 2023 financial results and recent corporate developments.

Today, we announced topline results from EMBARK, a double-blind placebo-controlled, Phase 3 clinical study of our gene therapy in patients with Duchenne muscular dystrophy.

Thank you, Assemblyman Hevesi, for your steadfast leadership on this important issue and for making a difference in the lives of Duchenne patients born in New York.

What’s in a gene therapy dose? It depends. How much gene therapy is needed depends on the nature of the disease being treated, and how many and what type of cells are affected. This video takes you inside the science to explore gene therapy and gene therapy dosing. Watch:

#WMS2023 is off to a great start! Stop by booth #13 to say hello and connect with the team in person.

We’re looking forward to connecting at #WMS2023 . See you in Charleston!